ReviewNature reviews. Endocrinology2013
HDL--is it too big to fail?
Review in Nature reviews. Endocrinology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- (Apo)Lipoprotein Profiling with Multi-Omics Analysis Identified Medium-HDL-Targeting PSRC1 with Therapeutic Potential for Coronary Artery Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Introduction to Mendelian randomization.Annals of clinical epidemiology · 2025Article
- High density lipoprotein particle size and function associate with new cardiovascular events in patients with chronic kidney disease.PloS one · 2025Article
- A combined observational and Mendelian randomization investigation reveals NMR-measured analytes to be risk factors of major cardiovascular diseases.Scientific reports · 2024Observational
- New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins.Diabetes & metabolism journal · 2022Review
- Functional Food and Bioactive Compounds on the Modulation of the Functionality of HDL-C: A Narrative Review.Nutrients · 2021Review
- The effect ofOncotarget · 2017Article
- Genetics of Triglycerides and the Risk of Atherosclerosis.Current atherosclerosis reports · 2017Review
- HDL as a Causal Factor in Atherosclerosis: Insights from Human Genetics.Current atherosclerosis reports · 2016Review
- Association of KCTD10, MVK, and MMAB polymorphisms with dyslipidemia and coronary heart disease in Han Chinese population.Lipids in health and disease · 2016Article
- SCARB1 Gene Variants Are Associated With the Phenotype of Combined High High-Density Lipoprotein Cholesterol and High Lipoprotein (a).Circulation. Cardiovascular genetics · 2016Article
- Mendelian randomisation study of the associations of vitamin B12 and folate genetic risk scores with blood pressure and fasting serum lipid levels in three Danish population-based studies.European journal of clinical nutrition · 2016Article
- The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.The lancet. Diabetes & endocrinology · 2014Review
- Treating low high-density lipoprotein cholesterol: what is the evidence?Therapeutic advances in endocrinology and metabolism · 2014Review
- The effect of a low-fat, plant-based lifestyle intervention (CHIP) on serum HDL levels and the implications for metabolic syndrome status - a cohort study.Nutrition & metabolism · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The HDL hypothesis has suffered damage in the past few years. Clinical trials have shown that raising HDL cholesterol levels does not improve cardiovascular disease (CVD) outcomes. In addition, Mendelian randomization studies have shown that DNA variants that alter HDL cholesterol levels in populations are unrelated to incident CVD events. Balancing this deluge of negative data are substantial basic science data supporting the concept that raising HDL cholesterol levels reduces CVD risk. Also, functionally relevant HDL subfractions might be more important determinants of risk than overall HDL cholesterol levels. But, while wobbly, the HDL hypothesis is still standing, seemingly too big to fail owing to past intellectual, economic and psychological investments in the idea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.